Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?

被引:316
|
作者
Cappelletti, Simone [1 ]
Daria, Piacentino [2 ]
Sani, Gabriele [2 ]
Aromatario, Mariarosaria [1 ]
机构
[1] Univ Roma La Sapienza, Dept Anat Histol Forens Med & Orthoped Sci, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Sch Med & Psychol, NESMOS Neurosci Mental Hlth & Sensory Organs Dept, I-00161 Rome, Italy
关键词
Abuse; caffeine; coffee; dependence; energy drinks; safety doses; toxicity; ENERGY DRINK CONSUMPTION; ADENOSINE A(2A) RECEPTOR; BLOOD-PRESSURE; COFFEE CONSUMPTION; PARKINSONS-DISEASE; MEMORY IMPAIRMENT; DIETARY CAFFEINE; HEART-DISEASE; SHORT-TERM; RAT MODEL;
D O I
10.2174/1570159X13666141210215655
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Caffeine use is increasing worldwide. The underlying motivations are mainly concentration and memory enhancement and physical performance improvement. Coffee and caffeine-containing products affect the cardiovascular system, with their positive inotropic and chronotropic effects, and the central nervous system, with their locomotor activity stimulation and anxiogenic-like effects. Thus, it is of interest to examine whether these effects could be detrimental for health. Furthermore, caffeine abuse and dependence are becoming more and more common and can lead to caffeine intoxication, which puts individuals at risk for premature and unnatural death. The present review summarizes the main findings concerning caffeine's mechanisms of action (focusing on adenosine antagonism, intracellular calcium mobilization, and phosphodiesterases inhibition), use, abuse, dependence, intoxication, and lethal effects. It also suggests that the concepts of toxic and lethal doses are relative, since doses below the toxic and/or lethal range may play a causal role in intoxication or death. This could be due to caffeine's interaction with other substances or to the individuals' preexisting metabolism alterations or diseases.
引用
收藏
页码:71 / 88
页数:18
相关论文
共 50 条
  • [11] Caffeine and cognitive performance: Persistent methodological challenges in caffeine research
    James, Jack E.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2014, 124 : 117 - 122
  • [12] The effects of a low dose of caffeine on cognitive performance
    Durlach, PJ
    [J]. PSYCHOPHARMACOLOGY, 1998, 140 (01) : 116 - 119
  • [13] DRUGS AND PLACEBOS - EFFECTS OF CAFFEINE ON COGNITIVE PERFORMANCE
    MITCHELL, VE
    ROSS, S
    HURST, PM
    [J]. PSYCHOLOGICAL REPORTS, 1974, 35 (02) : 875 - 883
  • [14] The effects of a low dose of caffeine on cognitive performance
    Paula J. Durlach
    [J]. Psychopharmacology, 1998, 140 : 116 - 119
  • [15] Electroporation as an Efficient Physical Enhancer for Skin Drug Delivery
    Juan Escobar-Chavez, Jose
    Bonilla-Martinez, Dalia
    Angelica Villegas-Gonzalez, Martha
    Luisa Revilla-Vazquez, Alma
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (11): : 1262 - 1283
  • [16] Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction
    Rogers, PJ
    Heatherley, SV
    Hayward, RC
    Seers, HE
    Hill, J
    Kane, M
    [J]. PSYCHOPHARMACOLOGY, 2005, 179 (04) : 742 - 752
  • [17] Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction
    Peter J. Rogers
    Susan V. Heatherley
    Robert C. Hayward
    Helen E. Seers
    Joanne Hill
    Marian Kane
    [J]. Psychopharmacology, 2005, 179 : 742 - 752
  • [18] Caffeine as a potential arousal enhancer: altered NMDA subunit gene expression without improving cognitive performance in REM sleep deprived rats
    Sahin, Leyla
    Cevik, Ozge Selin
    Koyuncu, Dilan Deniz
    Kocahan, Sayad
    [J]. CELLULAR AND MOLECULAR BIOLOGY, 2019, 65 (02) : 63 - 68
  • [19] CAFFEINE - THE MOST WIDELY USED PSYCHOACTIVE SUBSTANCE
    REGTS, JM
    DITZLER, TF
    [J]. JOURNAL OF COUNSELING AND DEVELOPMENT, 1987, 65 (10): : 571 - 571
  • [20] The effect of caffeine on cognitive task performance and motor fatigue
    van Duinen, H
    Lorist, MM
    Zijdewind, I
    [J]. PSYCHOPHARMACOLOGY, 2005, 180 (03) : 539 - 547